Effect of Fenofibrate on Serum Inflammatory Markers in Patients With High Triglyceride Values

Tsimihodimos, Vasilis; Kostoula, Angeliki; Kakafika, Anna I.; Bairaktari, Eleni; Tselepis, Alexandros D.; Mikhailidis, Dimitri P.; Elisaf, Moses

doi:10.1177/107424840400900i105

Cited by 61 publications

(43 citation statements)

References 39 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fibrates may also decrease plasma levels of inflammatory markers (e.g. CRP) that, in turn, influence MMP expression [279,280]. Based on these findings, it has been suggested that the fibrate-plus-statin combination could be a promising therapeutic strategy for diabetic atherosclerosis [281].…”

Section: Inhibition Of Metalloproteinases As Therapeutic Strategies Fmentioning

confidence: 99%

Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases

Gargiulo¹,

Gamba²,

Poli³

et al. 2014

CPD

View full text Add to dashboard Cite

Degradation of the extracellular matrix is an important feature of embryonic development, morphogenesis, angiogenesis, tissue repair and remodeling. It is precisely regulated under physiological conditions, but when dysregulated it becomes a cause of many diseases, including atherosclerosis, osteoarthritis, diabetic vascular complications, and neurodegeneration. Various types of proteinases are implicated in extracellular matrix degradation, but the major enzymes are considered to be metalloproteinases such as matrix metalloproteinases (MMPs) and disintegrin and metalloproteinase domain (ADAMs) that include ADAMs with a thrombospondin domain (ADAMTS).This review discusses involvement of the major metalloproteinases in some age-related chronic diseases, and examines what is currently known about the beneficial effects of their inhibitors, used as new therapeutic strategies for treating or preventing the development and progression of these diseases.

show abstract

Section: Inhibition Of Metalloproteinases As Therapeutic Strategies Fmentioning

confidence: 99%

Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases

Gargiulo¹,

Gamba²,

Poli³

et al. 2014

CPD

View full text Add to dashboard Cite

show abstract

“…Cerivastatin decreased serum CRP by 49.5% and fenofibrate by 29.8% (127). Micronized fenofibrate given daily in the dose of 200 mg to patients with hypertriglyceridemia reduced the serum levels of CRP by 34% (138). In a crossover study including otherwise healthy men with mixed dyslipidemia, the effects of fenofibrate, 200 mg daily, on CRP levels were compared with those of atorvastatin, 10 mg/daily for 10 weeks.…”

Section: Fenofibratementioning

confidence: 99%

C‐Reactive Protein (CRP)‐Lowering Agents

Prasad

2006

Cardiovascular Drug Reviews

237

185

View full text Add to dashboard Cite

C-reactive protein (CRP) plays a role in the pathogenesis of cardiovascular disease. It is a marker and predictor of cardiovascular disease. CRP possesses numerous cardiovascular effects (clotting, generation of oxygen radicals, increase in the expression of adhesion molecules and plasminogen activator inhibitor-1, plaque destabilization) that could result in cardiovascular disease. This review describes the effects of various cardiovascular drugs on the levels of CRP in health and disease. Cyclooxygenase inhibitors (aspirin, rofecoxib, celecoxib), platelet aggregation inhibitors (clopidogrel, abciximab), lipid lowering agents (statins, ezetimibe, fenofibrate, niacin, diets), â-adrenoreceptor antagonists and antioxidants (vitamin E), as well as angiotensin converting enzyme (ACE) inhibitors (ramipril, captopril, fosinopril), reduce serum levels of CRP; while enalapril and trandolapril have not been shown to have the same effect. Angiotensin receptor blockers (ARBs) (valsartan, irbesartan, olmesartan, telmisartan) markedly reduce serum levels of CRP. The findings with other ARBs (losartan and candesartan) were inconsistent. Antidiabetic agents (rosiglitazone and pioglitazone) reduce CRP levels, while insulin is ineffective. Calcium channel antagonists have variable effects on CRP levels. Hydrochlorothiazide and oral estrogen do not affect CRP. The CRP-lowering effect of statins is more pronounced than their lipid lowering effect and is not dependent on their hypolipemic activity. The effect of atorvastatin on CRP seems to be dose-dependent. CRP-lowering effect of statins is likely to contribute to the favorable outcome of statin therapy. The data suggest that lipid lowering agents, ACE inhibitors, ARBs, antidiabetic agents, antiinflammatory and antiplatelet agents, vitamin E, and â-adrenoreceptor antagonists lower serum or plasma levels of CRP, while vitamin C, oral estrogen and hydrochlorothiazide do not affect CRP levels.

show abstract

“…Following lower extremity bypass operations, elevated CRP levels are associated with an increased risk of graft occlusion and postoperative e v e n t s 2 3-2 5 . I n p a t i e n t s u n d e r g o i n g c a r o t i d 40 , statins (atorvastatin [41][42][43][44] , rosuvastatin 35,41,42 , fluvastatin 45 and pravastatin 46 ), fenofibrate 43,44,47 and ciprofibrate 48,49 . The mechanisms by which these drugs lower CRP levels are more extensively reviewed elsewhere 50 .…”

mentioning

confidence: 99%